Nav: Home

Clarifying the role of CHOP/GADD153 in cell death

May 13, 2016

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the May 2016 issue of Nature Communications demonstrate that CHOP/GADD153-dependent apoptosis reflects expression of the micro-RNA, miR-216b, during periods of endoplasmic reticulum (ER) stress.

The ER serves as a center for the maturation and folding of proteins. Stress occurs when protein production out-paces protein folding, for example when growing neoplasms create nutrient-deficient conditions. Misfolded proteins accumulate in the ER and trigger an adaptive stress reaction called the 'unfolded protein response' (UPR).

There are three ER trans-membrane proteins that act as UPR effectors: inositol-requiring enzyme (Ire1), protein kinase RNA-like ER kinase (PERK) and trans-membrane transcription factors ATF6 alpha/beta. Recent research has revealed that each of these three UPR branches regulates specific subsets of micro-RNAs. The decision to focus on CHOP was made because, while all three transducer protein groups are associated with both cell survival and cell death under various conditions, the CHOP/GADD153 transcription factor is a primary pro-apoptotic protein. Furthermore, it responds to both PERK and Ire1 signaling.

While the research team was focused on oncology, the direct insight their work provides into the molecular mechanisms of CHOP-dependent cell death has important implications in a variety of diseases.

"Our findings have very broad implications for a variety of biomedical indications, including metabolic disorders, neurodegenerative diseases and cancer," says J. Alan Diehl, Ph.D., Associate Director of Basic Sciences at the Hollings Cancer Center and senior author on the article. "This pathway regulates pancreatic and glucose homeostasis and therefore has implications for diabetes. In addition, protein mis-holding in the ER is at the core of the plaque formation we see in Alzheimer's and other neurodegenerative diseases. For quite some time, inhibitors of this pathway have been considered to be potential therapies and some small-molecule PERK inhibitors have been developed as anti-cancer therapies, but PERK promotes both cell survival and cell death, so distinguishing between what specific mechanistic pathways promote death versus survival is essential (to advance the development of these drugs). "

The primary challenge has been attributing the molecular mechanism of CHOP-dependent cell death into context due to the sheer number of apoptosis pathways that are regulated by transcription factors. "No single pathway is necessary for cell death to occur. Transcription factors regulate a broad base of genes that, in turn, regulate a system of signaling pathways, so you're left trying to figure out which pathway is dominant in cell-death decision-making," explains Diehl.

"We then needed to identify key targets of CHOP to elucidate the mechanistic pathway that drives apoptosis," says Diehl. The team, identified miR-216b in a screen established to identify small RNA mediators of UPR-dependent apoptosis and conducted three sets of experiments. Through a series of experiments, the team first established that miR-216b accumulated in the ER during periods of prolonged stress, not only during the UPR but also after exposure to the independent ER stress inducer thapsigargin, and also after exposure to chemotherapeutic agents that generate ER stress. In the next set of experiments, the team found that miR-216b accumulation requires PERK induction of CHOP/GADD153 that directly regulates miR-216b expression. The last set of experiments established that maximal expression of miR-216b is antagonized by Ire1, which led the team to conclude that miR216b accumulation reflects the convergence of PERK and Ire1 activity, and that by directly targeting c-Jun, miR-216b reduces AP-1-dependent transcription and sensitizes cells to apoptosis.

"Collectively, the work provides molecular insights into how CHOP regulates downstream targets and the ensuing biological impact of the micro-RNA and its targets. Our findings provide a link between multiple molecular pathways that are associated with cell death and demonstrate how CHOP regulates cell death thru the activated RNA," says Diehl.
-end-
About MUSC



Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.

Medical University of South Carolina

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...